vs
Amphastar Pharmaceuticals, Inc.（AMPH）とAMPCO PITTSBURGH CORP（AP）の財務データ比較。上の社名をクリックして会社を切り替えられます
Amphastar Pharmaceuticals, Inc.の直近四半期売上が大きい（$183.1M vs $104.4M、AMPCO PITTSBURGH CORPの約1.8倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs -55.2%、差は68.6%）。AMPCO PITTSBURGH CORPの前年同期比売上増加率が高い（11.5% vs -1.8%）。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$24.6M vs $-64.0K）。過去8四半期でAmphastar Pharmaceuticals, Inc.の売上複合成長率が高い（3.2% vs -2.6%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
アンプコ・ピッツバーグはペンシルベニア州ピッツバーグ中心部に本社を置く特殊鋼メーカーで、1929年に既存の複数の小規模鉄鋼メーカーが合併して設立されました。Ampcoを名付けた企業は複数存在するため、ミルウォーキーの銅基合金メーカーやマイアミのキャビネット企業など、他の同名企業と混同しないよう注意が必要です。
AMPH vs AP — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $104.4M |
| 純利益 | $24.4M | $-57.7M |
| 粗利率 | 46.8% | — |
| 営業利益率 | 19.4% | -54.0% |
| 純利益率 | 13.3% | -55.2% |
| 売上前年比 | -1.8% | 11.5% |
| 純利益前年比 | -35.7% | -1958.9% |
| EPS（希薄化後） | $0.51 | $-2.87 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $104.4M | ||
| Q3 25 | $191.8M | $103.7M | ||
| Q2 25 | $174.4M | $108.9M | ||
| Q1 25 | $170.5M | $99.2M | ||
| Q4 24 | $186.5M | $93.6M | ||
| Q3 24 | $191.2M | $92.1M | ||
| Q2 24 | $182.4M | $107.1M | ||
| Q1 24 | $171.8M | $110.0M |
| Q4 25 | $24.4M | $-57.7M | ||
| Q3 25 | $17.4M | $-2.2M | ||
| Q2 25 | $31.0M | $-7.3M | ||
| Q1 25 | $25.3M | $1.1M | ||
| Q4 24 | $38.0M | $3.1M | ||
| Q3 24 | $40.4M | $-2.0M | ||
| Q2 24 | $37.9M | $2.0M | ||
| Q1 24 | $43.2M | $-2.7M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | -54.0% | ||
| Q3 25 | 13.2% | 1.1% | ||
| Q2 25 | 24.2% | -2.8% | ||
| Q1 25 | 21.9% | 3.9% | ||
| Q4 24 | 24.2% | 5.5% | ||
| Q3 24 | 29.8% | 2.0% | ||
| Q2 24 | 30.3% | 4.7% | ||
| Q1 24 | 27.9% | 0.1% |
| Q4 25 | 13.3% | -55.2% | ||
| Q3 25 | 9.0% | -2.1% | ||
| Q2 25 | 17.8% | -6.7% | ||
| Q1 25 | 14.8% | 1.2% | ||
| Q4 24 | 20.4% | 3.3% | ||
| Q3 24 | 21.1% | -2.1% | ||
| Q2 24 | 20.8% | 1.9% | ||
| Q1 24 | 25.1% | -2.5% |
| Q4 25 | $0.51 | $-2.87 | ||
| Q3 25 | $0.37 | $-0.11 | ||
| Q2 25 | $0.64 | $-0.36 | ||
| Q1 25 | $0.51 | $0.06 | ||
| Q4 24 | $0.74 | $0.16 | ||
| Q3 24 | $0.78 | $-0.10 | ||
| Q2 24 | $0.73 | $0.10 | ||
| Q1 24 | $0.81 | $-0.14 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $10.7M |
| 総負債低いほど良い | $608.7M | $117.9M |
| 株主資本純資産 | $788.8M | $32.6M |
| 総資産 | $1.6B | $495.4M |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 3.61× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $10.7M | ||
| Q3 25 | $276.2M | $15.0M | ||
| Q2 25 | $231.8M | $9.9M | ||
| Q1 25 | $236.9M | $7.1M | ||
| Q4 24 | $221.6M | $15.4M | ||
| Q3 24 | $250.5M | $11.8M | ||
| Q2 24 | $217.8M | $7.9M | ||
| Q1 24 | $289.6M | $10.8M |
| Q4 25 | $608.7M | $117.9M | ||
| Q3 25 | $608.6M | $119.0M | ||
| Q2 25 | $607.7M | $115.9M | ||
| Q1 25 | $603.9M | $115.0M | ||
| Q4 24 | $601.6M | $116.4M | ||
| Q3 24 | $596.4M | $116.0M | ||
| Q2 24 | $586.9M | $119.4M | ||
| Q1 24 | $594.0M | $116.2M |
| Q4 25 | $788.8M | $32.6M | ||
| Q3 25 | $776.7M | $60.1M | ||
| Q2 25 | $757.5M | $62.7M | ||
| Q1 25 | $751.3M | $64.6M | ||
| Q4 24 | $732.3M | $58.9M | ||
| Q3 24 | $727.7M | $61.3M | ||
| Q2 24 | $713.3M | $58.0M | ||
| Q1 24 | $672.4M | $56.3M |
| Q4 25 | $1.6B | $495.4M | ||
| Q3 25 | $1.7B | $524.4M | ||
| Q2 25 | $1.6B | $537.2M | ||
| Q1 25 | $1.6B | $536.2M | ||
| Q4 24 | $1.6B | $530.9M | ||
| Q3 24 | $1.5B | $547.4M | ||
| Q2 24 | $1.5B | $560.8M | ||
| Q1 24 | $1.6B | $565.8M |
| Q4 25 | 0.77× | 3.61× | ||
| Q3 25 | 0.78× | 1.98× | ||
| Q2 25 | 0.80× | 1.85× | ||
| Q1 25 | 0.80× | 1.78× | ||
| Q4 24 | 0.82× | 1.98× | ||
| Q3 24 | 0.82× | 1.89× | ||
| Q2 24 | 0.82× | 2.06× | ||
| Q1 24 | 0.88× | 2.06× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $2.7M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $-64.0K |
| FCFマージンFCF / 売上 | 13.4% | -0.1% |
| 設備投資強度設備投資 / 売上 | 4.5% | 2.7% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | — |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $-8.1M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $2.7M | ||
| Q3 25 | $52.6M | $6.3M | ||
| Q2 25 | $35.6M | $-2.3M | ||
| Q1 25 | $35.1M | $-5.3M | ||
| Q4 24 | $29.0M | $7.5M | ||
| Q3 24 | $60.0M | $11.4M | ||
| Q2 24 | $69.1M | $-5.3M | ||
| Q1 24 | $55.3M | $4.5M |
| Q4 25 | $24.6M | $-64.0K | ||
| Q3 25 | $47.2M | $3.3M | ||
| Q2 25 | $25.0M | $-3.8M | ||
| Q1 25 | $24.4M | $-7.5M | ||
| Q4 24 | $16.6M | $3.7M | ||
| Q3 24 | $46.2M | $8.4M | ||
| Q2 24 | $63.1M | $-8.0M | ||
| Q1 24 | $46.5M | $1.7M |
| Q4 25 | 13.4% | -0.1% | ||
| Q3 25 | 24.6% | 3.2% | ||
| Q2 25 | 14.3% | -3.5% | ||
| Q1 25 | 14.3% | -7.5% | ||
| Q4 24 | 8.9% | 4.0% | ||
| Q3 24 | 24.1% | 9.1% | ||
| Q2 24 | 34.6% | -7.5% | ||
| Q1 24 | 27.1% | 1.5% |
| Q4 25 | 4.5% | 2.7% | ||
| Q3 25 | 2.8% | 2.9% | ||
| Q2 25 | 6.1% | 1.3% | ||
| Q1 25 | 6.3% | 2.2% | ||
| Q4 24 | 6.7% | 4.0% | ||
| Q3 24 | 7.2% | 3.2% | ||
| Q2 24 | 3.3% | 2.5% | ||
| Q1 24 | 5.1% | 2.6% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | -4.62× | ||
| Q4 24 | 0.76× | 2.40× | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | -2.64× | ||
| Q1 24 | 1.28× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
AP
| Forged And Cast Mill Rolls | $67.0M | 64% |
| Air Handling Systems | $14.3M | 14% |
| Heat Exchange Coils | $13.1M | 13% |
| Centrifugal Pumps | $10.3M | 10% |
| Forged Engineered Products | $4.0M | 4% |
